Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only
| Attribute | ||
|---|---|---|
Research Summary | Tesamorelin is the only growth hormone booster specifically proven to target and melt away hard, stubborn belly fat (visceral fat). It was literally FDA-approved just for this purpose. | Ipamorelin is the cleanest growth hormone booster. It gently nudges your brain to release growth hormone without making you hungry or raising your stress hormones. It is perfect for steady, long-term anti-aging. |
Studied For | HIV-associated lipodystrophy (FDA approved)Hepatic fat / NAFLD researchCognition research in aging/HIVGH deficiencyBody composition improvementVisceral adipose reductionLiver fat reductionGH axis stimulationIGF-1 elevationCardiovascular lipid profile improvementCognitive decline in aging HIV+ populationAnti-aging via GH axisNon-alcoholic fatty liver diseaseLean mass supportvisceral fat reductionbelly fatHIV lipodystrophymuscle growthbody compositionlipid profile improvementcognitive function | GH secretagogue researchAnti-aging / longevity via GH axisBody composition improvementLean muscle gainFat loss via GHSleep quality / GH rhythmRecoveryBone density via GHIGF-1 elevationPulsatile GH release simulationStacked with CJC-1295 (no DAC)GI motility researchMetabolic rate improvementCollagen synthesis via GHAthletic performanceanti-agingmuscle growthfat lossrecoverydeep sleepbone densitycellular repairGH pulse stimulation |
Research Areas | Performance & MuscleMetabolicWeight Management & Fat LossJoint & Bone SupportCognitive | Performance & MuscleLongevityMetabolicJoint & Bone SupportSleep & Circadian |
Best Stacked With | ipamorelincjc-1295-no-dacl-carnitinebac-water | cjc-1295-no-dacsermorelinghrp-2bac-water |
Overview | ||
Category | Muscle Growth & Performance | Muscle Growth & Performance |
Compound Class | Synthetic GHRH analog with trans-3-hexenoic acid modification at N-terminus; FDA-approved for HIV lipodystrophy | Selective synthetic pentapeptide GH secretagogue (GHRP); minimal cortisol/prolactin side effects |
Molecular Target | GHRH receptor (GHRHR) on pituitary somatotrophs; GH/IGF-1 axis stimulation; preferential visceral fat metabolism | GHS-R1a (ghrelin receptor) agonist; highly selective for pituitary GH release without significant ACTH/cortisol elevation |
Aliases / AKA | EgriftaEgrifta SVTH9507Tesamorelin acetateTrans-3-hexenoic acid GHRHModified GHRH analog Egrifta | NNC 26-0161NNC26-0161Ipamorelin acetateGHRP-1a analogSelective GHRPIpamorelin peptide |
Parent Compound | Growth hormone releasing hormone | Ghrelin mimetic |
Molecular Weight | 5135.9 Da | 711.85 Da |
Amino Acid Sequence | hGHRH(1-44) with trans-3-hexenoyl | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
CAS Number | 218949-48-5 | 170851-70-4 |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | No | No |
GLP-1 Class | No | No |
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | ||
PubMed Citations | 125 Moderate | 1,192,840 Extensive |
Clinical Trials | 1010 Active | Not Listed |
Regulatory Status | FDA-approved (Egrifta) for HIV lipodystrophy; WADA S2. | Not FDA-approved; research chemical; WADA S2. |
Evidence & Regulatory | ||
Half-Life | ~26-38 minutes | ~2 hours |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | Strong human randomized trials show roughly 15 to 18 percent visceral-fat reduction over 26 weeks with reduced triglycerides and reduced liver fat. It is FDA-approved for HIV-associated lipodystrophy. | Preclinical work established growth-hormone release with no rise in cortisol or prolactin. A human GI-motility program was run and discontinued for non-safety reasons. |
Side Effects Noted | Joint pain, injection-site reactions, peripheral edema, paresthesia, reduced glucose tolerance and elevated IGF-1. | Best tolerated of the GHRPs; injection-site reactions, flushing, headache, mild water retention; limited human data. |
Warnings | Contraindicated in active malignancy, pituitary disorders, and pregnancy; monitor IGF-1 and glucose. Benefit reverses on discontinuation. WADA-prohibited (needs a therapeutic-use exemption). | Not approved; growth-hormone-axis risks apply with sustained use. WADA-prohibited. Research use only. |
Pharmacology | ||
Form | lyophilized | lyophilized |
Diluent | sterile water | bacteriostatic or sterile water |
Storage Temp | per formulation (room temp or refrigerated); follow label | cold, dark |
Light Sensitive | Yes | Yes |
Freeze / Thaw | avoid | avoid |
Handling Notes | Daily subcutaneous; improper reconstitution causes aggregation. | Most selective GHRP; often paired with a GHRH analog. |
Reconstituted Shelf Life | 1 Days Refrigerated | 28 Days Refrigerated |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Two leading tissue-repair peptides with distinct healing mechanisms.
A systemic repair peptide versus a copper peptide for tissue and skin research.
A GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis.
A dual incretin agonist versus an amylin analog in metabolic research.
A triple incretin agonist versus an amylin analog in weight research.
Two metabolic research compounds targeting mitochondrial and NNMT pathways.
NAD+ metabolism versus a mitochondrial-derived peptide in longevity research.
Two copper research peptides studied for skin and hair.
A long-acting versus a short-acting GHRH analog.
A selective versus a first-generation ghrelin-receptor secretagogue.
A GLP-1 agonist versus a GLP-1/amylin combination in metabolic research.
Two peptides studied for gut and mucosal repair.
Melanocortin versus oxytocin pathways in intimacy and libido research.
Two thymic immune-modulating research peptides.
An anxiolytic nootropic versus a sleep-associated research peptide.
Direct IGF-1 signaling versus myostatin inhibition in muscle research.
A mitochondrial-targeted peptide versus NAD+ in cellular-energy research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.
